Under the agreement, the two companies will combine in an all-stock transaction to create a new company. Each outstanding share of Uroplasty’s common stock will be exchanged for 3.6331 shares of Vision-Sciences’ common stock. Additionally, Uroplasty and Vision-Sciences’ U.S. sales teams will market Vision-Sciences’ proprietary EndoSheath Endoscopy technology platform.
The transaction is expected to close in the first half of 2015, and the combined company will conduct business as Cogentix Medical.
More articles on gastroenterology:
Prevea Pediatric Digestive Health adds Dr. Maridine Co
KARL STORZ Endoscopy-America’s visualization enhancement system is a 2014 Innovation of the Year
Dr. Michael Goebel joins Hattiesburg Clinic Gastroenterology
